There’s no stopping in this multibagger smallcap pharmaceutical stock!

Lyka Labs maintains high quality and GMP/GLP standards in the manufacturing and testing of its products. The company manufactures pharmaceutical products such as Dry Powder, Liquid and Lyophilised Injections and external preparations and cosmetics covering various therapeutic areas. The company is also engaged in manufacturing on a P2P basis and job work basis for Covid 19 medicines.

The company’s R&D centre is engaged in the development of new formulations and has successfully developed several products in the following product categories: 1. Injectables- Liquid Injections, Lyophilised Injections in anti-bacterial, antifungal, NSAIDS, Proton Pump Inhibitors and Anaesthetics. 2. Topical preparations: Ointments/Creams and Lotions. 

The company is also modernizing its existing manufacturing facilities to improve throughput and reduce manufacturing costs thereby increasing profitability.

To meet the increase in demand for lyophilised products the company has embarked on an expansion project of its Lyophilization Plant at its Ankleshwar factory. This project is likely to be completed in 9-12 months with a 50% capacity enhancement for lyophilisation. The company has received permission to manufacture and marketing of Liposomal Amphotericin B Injection 50 mg/vial from the Government of India, Directorate General of Health Services, New Delhi.

Interestingly, the stock has lately caught the eyes of market participants and it is quite evident from the price movement. The stock is locked at an upper circuit at the time of writing this article and it has marked a fresh 52-week high on Tuesday.

The stock has recorded over a 10-fold jump in its price from the March 2020 lows to the high of Tuesday. On an MTD basis also it has outperformed the headline indices and jumped more than 20%. The stock has a Price Strength (RS Rating) of 94 which is great indicating the outperformance as compared to other stocks. However, despite this outperformance, what is more intriguing is the fact that the stock has recently witnessed a breakout of the stage-4 consolidation pattern, the depth of which is nearly 35%.